Company ProfilePremium

Aprogen Healthcare & Games Inc.

Company Profile Analysis

Ticker: 109960.KQ주식회사 앱토크롬

ESOMAR 23 Corporate BadgeISO Certifications Badge
Aprogen Healthcare & Games Inc. - Company showcase

Year Founded & Workforce

1998

18 Employees

Aprogen Healthcare & Games Inc. logo

Aprogen Healthcare & Games Inc. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Aprogen Healthcare & Games Inc. Overview

APTOCROM is a very small KOSDAQ-listed company inside the Aprogen biopharmaceutical group, which is controlled by Kim Jae-seop through his holding company G-Base. Its stated operating businesses are wholesale and retail distribution of pharmaceuticals (dermatologicals, gastrointestinal drugs, tonics and antibiotics) and leasing of owned real estate, machinery and equipment. Group-level reporting since 2020 has described its function as sales of pharmaceuticals and asset leasing. In practice, its economic profile is dominated by its role as a group financing vehicle rather than by operations. It carries a balance sheet of roughly KRW 320 bn against annual revenue under KRW 10 bn. It has channeled large sums into parent Aprogen's biosimilar programs: KRW 50 bn to trastuzumab biosimilar AP063 in 2023 and a KRW 70 bn cost-sharing commitment to adalimumab biosimilar AP096 in 2024. In August 2025 it added blockchain and virtual-asset activities to its articles of incorporation. Its equity story therefore turns on related-party asset recovery rather than on distribution economics.


Company's own description (from filings)

The Q1 2026 quarterly report filed on KIND describes the company (formerly AP Healthcare) as founded in February 1998 and engaged in pharmaceutical wholesale/retail and leasing (KIND Q1 2026 report, filed 14 May 2026). An August 2025 Asia Economy article summarizing disclosures was more specific. It described the pharmaceutical business as distribution and sale centered on external-use (dermatological) preparations, digestive-system drugs, tonics/nutritional preparations and antibiotic preparations. It described the leasing business as rental of owned real estate, machinery and equipment (Asia Economy, 11 Aug 2025).

Business model and revenue model

DimensionCharacterizationBasis
Revenue modelPredominantly product resale (merchandise distribution) plus rental income; no subscription or licensing revenue disclosedFiling descriptions, 2025–2026
Product vs. service mixProduct distribution plus leasing; exact split not publicly disclosed in sources reviewed—
Value-chain positionDownstream intermediary (wholesale/retail) in Korean pharmaceutical distribution; asset lessorFilings
Customer typesNot publicly disclosed (typical counterparties for Korean pharmaceutical wholesalers are pharmacies; clinics and hospitals)—
End-marketsSouth Korean domestic pharmaceutical market; domestic commercial real-estate rental (Seongnam)Filings; KIND asset tables
Related-party economic interestsRevenue-linked "dividend" rights on AP096 (adalimumab biosimilar) under a KRW 70 bn cost-sharing contract with Aprogen; prior KRW 50 bn funding of AP063 (trastuzumab biosimilar); holdings of Aprogen convertible bondsDealsite, 20 Sep 2024; NewDaily, 23 Sep 2024; DigitalToday, 31 Mar 2026
New statutory business objectivesBlockchain and virtual-asset business, blockchain/virtual-asset investment, blockchain/virtual-asset finance, and ancillary services/installation, added at the 22 Aug 2025 EGMAsia Economy, 11 Aug 2025

Legacy businesses (pre-2024)

Before it became a pure distribution/leasing entity, the company (as Aprogen H&G) was described by aggregators as a mobile-game publisher that also provided domestic wireless lighting-control services and telecommunications/wireless solutions (Morningstar; CB Insights). Statbase's legacy management list includes a head of a Light Control Division, a head of a Wireless Solution Business Division and an R&D Center chief, consistent with that profile. The largest legacy game title was the mobile game Fortress M. Its publishing contract was terminated early in February 2021, removing about KRW 7.6 bn of sales; the then-parent Aprogen Pharmaceuticals said this equalled 15% of its own consolidated revenue. Management said it would offset the gap by publishing Trove and Dragon Raja Origin and further titles (Asia Economy English, 19 Feb 2021). The FY2025 revenue decline was attributed only to a "slowdown in a subsidiary's business," and the subsidiary was not named in the excerpts reviewed (FY2025 earnings-variance disclosure, 27 Feb 2026).

Independent characterization

On the numbers, APTOCROM's operating businesses are sub-scale. Consolidated FY2025 revenue was KRW 9.81 bn with an operating loss of KRW 2.29 bn, against total assets of about KRW 320 bn (FY2025 audited summary, 30 Mar 2026). An asset-to-revenue ratio above 30x means the operating business is not the main driver of value. What drives value is the recoverability of (i) related-party claims on Aprogen biosimilar programs, (ii) Aprogen-issued securities (such as the KRW 40 bn 27th-series CB it is selling), and (iii) its Seongnam real estate. Analytically, it behaves like a captive treasury or holding vehicle of the Aprogen group, with a small distribution business attached. The renaming to APTOCROM alongside a crypto/blockchain charter amendment fits a 2025 KOSDAQ pattern: other small caps such as Hyper Corporation, Parataxis Korea and Someage saw share-price spikes after announcing virtual-asset pivots (Asia Economy, 11 Aug 2025). No operating crypto revenue has been disclosed.

Strategy

The company has published no investor-day material and no strategy narrative from its annual report was retrievable. The strategy is therefore reconstructed from its disclosed actions over the last 24 months:

Context: the reverse split coincided with a broader rush of capital reductions. Between 1 Jan and 26 Mar 2026, 82 such decisions were filed on KOSPI and KOSDAQ, against 19 in the same period of 2025. Media linked the surge to regulators' stated intent to push "coin stocks" (shares below KRW 1,000) out of the market (Daum/news, 30 Mar 2026). APTOCROM traded at about KRW 164–193 before the split.

Medium-term financial targets and guidance: none published. ESG commitments and cost programs: none disclosed.

Product Portfolio

Business lineOfferingDescription / statusTarget customerLaunch / versionPricingSource

Pharmaceutical distribution

Dermatological (external-use) preparations

Distributed and sold; brands not disclosed

———

Asia Economy, 11 Aug 2025

Pharmaceutical distribution

Digestive-system drugs

Distributed and sold; brands not disclosed

———

Same

Pharmaceutical distribution

Tonics / nutritional preparations

Distributed and sold; brands not disclosed

———

Same

Pharmaceutical distribution

Antibiotic preparations

Distributed and sold; brands not disclosed

———

Same

Leasing

Real estate (land and buildings, Seongnam)

Investment-property rental; land carrying value ~KRW 3.57 bn, buildings ~KRW 4.74 bn (Q1 2026 report table)

Commercial tenants (not named)

Ongoing

Lease rates not disclosed

KIND Q1 2026 report

Leasing

Machinery and equipment

Rental of owned equipment

—

Ongoing

—

Asia Economy, 11 Aug 2025

Biosimilar economic interest

AP096 (adalimumab / Humira biosimilar)

Cost-sharing investor; entitled to sales-linked dividends after commercialization; parent guided clinical supply in H1 2025, trials to 2027, launch as early as 2028

—

Development stage

KRW 70 bn commitment

Dealsite, 20 Sep 2024

Biosimilar economic interest

AP063 (trastuzumab / Herceptin biosimilar)

KRW 50 bn development funding in 2023; parent ran a global Phase 3 in 19 countries / 147 sites / 720 patients

—

Phase 3 (parent)

—

NewDaily, 23 Sep 2024; Asia Economy, 27 Jul 2023

New business (chartered)

Blockchain / virtual-asset business, investment and finance

Added to articles Aug 2025; no product, licence or revenue disclosed

—

Not launched (as far as disclosed)

—

Asia Economy, 11 Aug 2025

Legacy (historical)

Mobile game publishing (Fortress M; Trove; Dragon Raja Origin)

—

Consumers

2020–2021

—

Asia Economy English, 19 Feb 2021

Legacy (historical)

Wireless lighting-control services; wireless/telecom solutions

—

B2B

Pre-2017

—

Morningstar; CB Insights

“—” = not publicly disclosed.

Financial Narrative

Basis: K-IFRS consolidated, KRW bn, fiscal years ending 31 December. FY2025 uses the audited figures reported with the AGM results (30 Mar 2026). FY2024 uses the comparative column of the FY2025 earnings-variance disclosure (27 Feb 2026). FY2018–FY2019 context appears in 6.6.

Income statement

Notes and source conflicts:

FY2025 pre-tax figure: (−KRW 6.43 bn) is from the preliminary disclosure.

Separate (parent-only) FY2025: revenue KRW 7.40 bn, operating loss KRW 1.16 bn, net loss KRW 3.47 bn, EPS −KRW 16 (AGM results, 30 Mar 2026).

Gross profit: Statbase reports a TTM gross profit of about KRW 1.71 bn on about KRW 9 bn of TTM revenue to 31 Mar 2026 (≈19% gross margin).

EPS after the reverse split: Judal shows trailing EPS of KRW 3,299 and P/E of 0.57x (Oct 2026). That implies a large positive H1 2026 net profit, perhaps from a non-operating gain. Treat it with caution.

Growth

The FY2019–FY2025 CAGR is computed from FY2019 revenue of KRW 21.9 bn (Asia Economy, 28 Jan 2020) and FY2025 revenue of KRW 9.81 bn. Simply Wall St separately reports average annual revenue growth of 11.8% over its look-back window (TTM to 30 Sep 2025). That conflicts directionally with the FY2019–FY2025 trajectory because the window and base years differ.

Balance sheet

Additional balance-sheet data points:

Cash and equivalents: not publicly disclosed in sources reviewed. At end-Q2 2024, consolidated current assets were about KRW 24 bn (NewDaily, 23 Sep 2024).

Total debt (short/long split): not fully disclosed. The Q1 2026 report lists secured short-term borrowings of KRW 3.5 bn from Kookmin Bank (collateral: PP&E land/buildings) and KRW 2.0 bn from Hana Bank (collateral: investment-property land/buildings), with collateral of KRW 9.36 bn set on each (KIND Q1 2026 report excerpt). The KRW 40 bn 6th-series BW issued in July 2023 was "partially redeemed" by Q1 2026, with original maturity 25 Jul 2026.

Net debt: not computable without a verified cash figure. The low liabilities (KRW 13.9 bn total at FY2025) suggest gross debt is small relative to equity.

Goodwill & intangibles: not publicly disclosed in sources reviewed.

Working capital: not publicly disclosed in sources reviewed.

Related-party/financial assets: the company held Aprogen's KRW 40 bn 27th-series CB, under a sale agreement since April 2024 (DigitalToday, 31 Mar 2026). It also funded KRW 50 bn for AP063 (2023) and committed KRW 70 bn for AP096 (2024–2025).

Capital reduction: The 20:1 consolidation approved on 30 Mar 2026 reduces share capital from about KRW 110.4 bn to about KRW 5.5 bn in order to offset accumulated deficits (Dealsite, 23 Feb 2026). This changes equity composition, not total equity.

Cash flow

Notes: Cash-flow statements were not accessible. For the 27th CB sale, the contractual receipts are KRW 2 bn (5 Apr 2024) and KRW 15 bn (28 Oct 2024) in FY2024, then KRW 5 bn (8 Jan 2025) and KRW 2 bn (24 Oct 2025) in FY2025. The KRW 16 bn balance was rescheduled to 17 Apr 2026, extendable to 30 Jun 2026 (DigitalToday, 31 Mar 2026). The FY2024 offering was planned at KRW 50 bn, with uses of KRW 38.4 bn operating funds (of which KRW 35 bn for AP096), KRW 11 bn debt repayment (BW put) and KRW 0.6 bn other (Dealsite, 20 Sep 2024). There were no dividends; Simply Wall St reports no dividend history.

Ratios

Not computable from verified data: ROIC, current ratio, net debt/EBITDA, interest coverage, cash conversion cycle. Simply Wall St shows ROE of −21.61% and net margin of −549.87% on a TTM basis to 30 Sep 2025. That window includes the heavy Q4 2024 losses and differs from the fiscal-year figures above.

Historical context (pre-FY2021)

FY2019 is from Asia Economy English (28 Jan 2020). FY2018 revenue and operating income are back-computed from the reported FY2019 growth rates (+12.7% revenue; operating loss up 269.5%) and are approximate.

Trend commentary

  1. Shrinking operating base. Revenue has fallen from about KRW 21.9 bn (FY2019, when games were still material) to KRW 16.4 bn (FY2024) and KRW 9.8 bn (FY2025). The 40% FY2025 drop was attributed to subsidiary slowdown (27 Feb 2026 disclosure). The loss of Fortress M in 2021 marked the start of the decline of the game business.

  2. Operating breakeven lost. FY2024's small operating profit (KRW 0.97 bn) turned into a KRW 2.29 bn loss in FY2025. With fixed costs for a listed entity and very small revenue, operating leverage works against the company.

  3. Below-the-line losses dominate. In FY2024 the pre-tax loss (−KRW 26.3 bn) was about 27x larger than operating profit. Management said the FY2025 loss narrowed thanks to higher finance income and lower expenses.

  4. Balance sheet de-levered, equity flat. Liabilities fell from KRW 33.0 bn to KRW 13.9 bn in FY2025. That fits with the partial BW redemption and CB-sale proceeds. Equity rose slightly despite the net loss because share capital increased by KRW 10 bn (20 m new shares; the issuance event was not identified).

  5. Confirmation requires the H1 2026 semi-annual report.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Structure

LayerEntityRole / relationshipSource

Ultimate controller

Kim Jae-seop (김재섭)

100% owner of G-Base; Aprogen founder; director of APTOCROM

Asia Economy, 6 Feb 2020; AGM results 30 Mar 2026

Top holding company

G-Base Co. (지베이스)

Largest shareholder of Aprogen (25.81% per Newstomato)

Newstomato (IB Tomato)

Listed parent

Aprogen Inc. (KOSPI 007460)

Largest shareholder of APTOCROM (71.66%, Aug 2025)

DigitalToday, 22 Aug 2025

Listed sister

Aprogen Biologics Inc. (KOSPI 003060; formerly Aprogen Pharmaceuticals)

Former 20.06% holder of APTOCROM; CMO / Osong plant

Asia Economy, 11 Aug 2025; MarketScreener

Affiliate

Nexconics (넥스코닉스)

Group IT affiliate; 9.52% holder of Aprogen; subscriber to the May 2026 APTOCROM placement

Asia Economy, 6 Feb 2020; Newstomato; DigitalToday, 28 Apr 2026

Subject company

APTOCROM Inc. (KOSDAQ 109960)

Pharmaceutical distribution, leasing, group funding

Filings

Subsidiaries of APTOCROM

—

AGM results disclosure, 30 Mar 2026

—

Revenue by Segment

MetricFY2024FY2025

Consolidated revenue (KRW Bn)

16.409.81

Parent-only (separate) revenue (KRW Bn)

—7.40

Implied subsidiaries' net contribution to revenue (KRW Bn, computed)

—2.41

Parent-only operating income (KRW Bn)

—-1.16

Implied subsidiaries' operating income (KRW Bn, computed)

—-1.13

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Per-Share Data

MetricFY2024FY2025

Revenue (KRW Bn)

16.409.81

Operating income (KRW Bn)

0.97-2.29

Pre-tax income from continuing ops (KRW Bn)

-26.34-6.43

Net income (KRW Bn)

-28.02-5.63

Basic EPS (KRW, pre-reverse-split)

—-26

Dividends per share (KRW)

00

Operating margin (%)

5.9-23.3

Net margin (%)

-170.9-57.4

Margin Analysis (%)

MetricFY2025

Revenue growth YoY (%)

-40.2

Revenue CAGR FY2019–FY2025 (%, computed)

-12.5

Balance Sheet and Margin Analysis (%)

MetricFY2024FY2025

Total assets (KRW Bn)

334.89320.46

Total liabilities (KRW Bn)

33.0413.89

Total equity (KRW Bn)

301.86306.57

Share capital (KRW Bn)

100.39110.39

Shares outstanding (m, computed from capital at KRW 500 par)

200.79220.79

Liabilities to equity (%)

10.94.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Returns & Leverage Ratios

MetricFY2023FY2024FY2025

Dividends paid (KRW Bn)

—00

Equity raised — public offering (KRW Bn, planned size)

—50.0—

Biosimilar cost-sharing outflow committed (KRW Bn)

50.035.035.0

Proceeds received from sale of Aprogen 27th CB (KRW Bn, contractual schedule)

—17.07.0

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2024FY2025

ROE (%, computed on ending/average equity)

-9.3-1.8

ROA (%, computed)

-8.4-1.7

Asset turnover (x, computed)

0.050.03

Liabilities / equity (x)

0.110.05

Income Statement

MetricFY2018FY2019

Revenue (KRW Bn)

19.421.9

Operating income (KRW Bn)

-0.21-0.77

Net income (KRW Bn)

—-9.39

Share Price History

DateReported price (KRW)BasisPost-split equivalent (KRW)Source

19 May 2025

341

Pre-split

6,820

Simply Wall St

11 Aug 2025

455

Pre-split (limit-up)

9,100

Asia Economy

22 Aug 2025

398

Pre-split

7,960

DigitalToday

23 Feb 2026

193

Pre-split

3,860

DigitalToday

31 Mar 2026

164

Pre-split

3,280

DigitalToday

28 Apr 2026

178

Pre-split

3,560

DigitalToday

15 Jul 2026

1,696

Post-split

1,696

Asia Economy quote

13 Oct 2026

1,890

Post-split

1,890

Judal

Metric

1 year

3 years

5 years

—

Share-price change (%)

not computed

not computed

not computed

—

Valuation Multiples

MultipleAPTOCROMBasis

Market cap (KRW Bn)

28.5

Judal, 13–14 Oct 2026

P/B (x)

0.09

KRW 28.5 bn ÷ FY2025 equity KRW 306.6 bn (Judal shows 0.08x)

P/S (x)

2.9

÷ FY2025 revenue KRW 9.81 bn

P/E (x, trailing)

0.57–0.58 (Judal); FY2025 basis negative / not meaningful

—

EV/EBITDA (x)

Not meaningful (EBITDA not disclosed; negative operating income)

—

Capital Markets

ItemStatusSource

Sell-side analyst consensus

None identified. Judal "AI equity research" pages (Buy, KRW 9,600 targets, etc.) are machine-generated and are not treated as analyst consensus

Judal, Oct 2026

Dividend history / policy

No dividend record

Simply Wall St

Buyback authorizations

None disclosed. Simply Wall St shows a buyback yield of −59.3%, reflecting net share issuance

Simply Wall St

Debt maturity profile

6th BW: maturity 25 Jul 2026 (partially redeemed by Q1 2026); bank short-term borrowings KRW 3.5 bn (KB) + KRW 2.0 bn (Hana), maturities not disclosed

KIND Q1 2026 excerpt

Share count history

~113.8 m (pre-Oct 2024, computed) → 200.79 m (end-2024) → 220.79 m (end-2025) → 11.04 m (post 20:1) → ~15.13 m (post placement, computed)

Asia Economy, 8 Oct 2024; capital figures from disclosures

Analyst Conclusions

Guidance and expectations

Management has published no revenue or earnings guidance. There is no consensus. The only forward-looking statements on record are (i) the parent's AP096 timeline (clinical work to 2027, launch as early as 2028) and (ii) the company's 2024 expectation of dividend receipts from 2027 and full recovery of the investment around 2030 if development succeeds (Asia Economy, 8 Oct 2024; Dealsite, 20 Sep 2024).

Bull case

  1. Deep asset discount. Book equity of KRW 306.6 bn against a market cap of about KRW 28.5 bn (P/B ~0.09x). Even heavy haircuts on related-party assets could leave value above the current price.

  2. Cash conversion of the CB sale. Collecting the KRW 16 bn balance on the Aprogen 27th CB would equal over half of the current market cap in cash.

  3. Biosimilar optionality. If AP063/AP096 reach market (regulatory easing cited by the parent), contractual sales-linked dividends could exceed the company's entire current revenue base.

Bear case

  1. Circularity of value. Much of the asset base appears to consist of claims on, or securities of, a parent that loses about KRW 97.5 bn a year at the operating level (TTM). Book value may overstate recoverable value, as the FY2024 KRW 26 bn below-the-line loss suggests.

  2. Minority dilution as the funding model. The 2024 offering (~87% new shares) and the 2026 affiliate placement (~37%) show repeated recapitalizations at minority shareholders' expense. A 20:1 consolidation was also needed to escape penny-stock status.

  3. Shrinking operations and narrative churn. Revenue fell 55% between FY2019 and FY2025. There have been three corporate names in about 18 months, and a crypto charter has produced no disclosed operations, which signals strategic drift.

Key catalysts and monitorables (next 12 months)

MonitorableWhy it mattersExpected timing
H1 2026 semi-annual and Q3 2026 quarterly reportsVerify the positive TTM earnings implied by aggregators; identify the gain sourceReleased Aug 2026; Q3 due by mid-Nov 2026
Final settlement of the Aprogen 27th CB sale (KRW 16 bn balance)Liquidity and asset qualityDue 17 Apr 2026, extendable to 30 Jun 2026; confirm outcome
Disclosure of the acquisition funded by the KRW 12 bn placementStrategic direction; related-party characterPending
6th-series BW maturity (25 Jul 2026)Confirm full repaymentPassed; confirm
AP096 / AP063 clinical and regulatory progress at AprogenUnderpins the value of biosimilar claimsOngoing
Any crypto/blockchain licence, partnership or revenueTests credibility of the 2025 pivotNot scheduled
FY2026 business report and AGM (≈Mar 2027)Audited asset values; board changesQ1 2027
Lock-up expiry on Nexconics placement sharesPotential supply~17 Jun 2027

Analyst verdict

APTOCROM, formerly Aprogen Healthcare & Games and then AP Healthcare, should not be analyzed as a pharmaceutical distributor. Its operating business is too small to anchor value: KRW 9.8 bn of revenue and an operating loss of KRW 2.3 bn in FY2025. Seventeen or eighteen employees cannot credibly sustain an independent strategy in Korean pharmaceutical wholesale, a market dominated by large-scale private distributors. The listed shell's real function since entering the Aprogen group in 2017–2018 has been as a capital conduit. It raised equity and debt from public markets and redeployed the proceeds into parent and affiliate instruments: Aprogen KIC's KRW 70 bn CB in 2018, KRW 50 bn for AP063 in 2023, KRW 70 bn committed to AP096 in 2024–2025, and the KRW 40 bn Aprogen 27th CB, now being sold in delayed installments.

The investment debate therefore reduces to one question: how much of roughly KRW 307 bn of book equity is recoverable cash, rather than accounting value attached to a parent burning close to KRW 100 bn a year at the operating level? The market's answer, a P/B near 0.09x, is a heavy discount. That discount looks rational given FY2024's KRW 26 bn non-operating loss, the rescheduling of CB receipts, affiliate ownership near 80% and only one independent director. The 2025 crypto rebrand and 2026 reverse split addressed the share price and exchange-compliance optics, not fundamentals.

Upside exists. A clean collection of the KRW 16 bn CB balance or an AP096/AP063 commercial milestone could re-rate the shares sharply from such a depressed base. Those catalysts, however, sit largely outside the company's control and depend on a financially strained parent. Pending verification of H1 2026 earnings and the undisclosed acquisition target, the profile is best described as a high-risk, related-party-dependent special situation with weak minority protections.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NamePositionTenure / statusBackground (as disclosed)Born

Kim Jeong-chul (김정출)

Representative Director (CEO)

———

Kim Jae-seop (김재섭)

Inside (executive) director

Re-elected 30 Mar 2026, 3-year term

Inside director of G-Base (his 100%-owned holding company); founder of Aprogen (est. 2000, KAIST-linked) and its chairman/CEO

Jan 1963

Kang Seong-ho (강성호)

Inside director

Newly elected 30 Mar 2026, 3-year term

——

Lee Jong-seop (이종섭)

Outside (independent) director

Re-elected 30 Mar 2026, 3-year term; 6 years cumulative tenure including the new term

Head director of Ansan Yonsei Hospital

—

“—” = not publicly disclosed.

Major Shareholders

HolderStakeDate / basisSource

Aprogen Inc.

71.66%

21 Aug 2025, after an 18 Aug 2025 off-market purchase of 40,269,859 shares at KRW 317

DigitalToday, 22 Aug 2025

Aprogen Inc. (prior)

53.42%

26 Jun 2025 report basis

DigitalToday, 22 Aug 2025

Aprogen Inc. / Aprogen Biologics (alternate prior figures)

48.78% / 20.06%

Reported 11 Aug 2025 (data date likely pre-transfer)

Asia Economy, 11 Aug 2025

Aprogen Inc. (2024)

~42%

Sep 2024

Dealsite, 20 Sep 2024

Nexconics (affiliate)

~27.0% (computed)

Post-May-2026 placement of 4,092,770 shares out of ~15.13 m total; 1-year lock-up

DigitalToday, 28 Apr 2026 (computation by author)

Aprogen Inc. (post-placement, computed)

~52.3% (computed)

71.66% × 11,039,463 ÷ 15,132,233; assumes no other changes

Author computation

Combined affiliates (computed)

~79%

Post-placement

Author computation

Competitive Landscape

Competitors by Segment

ArenaCompetitor / comparatorRelevanceComparative revenueSource / note

Korean pharmaceutical wholesale

Geo-Young (지오영)

Largest Korean pharmaceutical wholesaler (private)

——

Korean pharmaceutical wholesale

Baekje Pharm (백제약품)

Major private wholesaler

—

Same

Korean pharmaceutical wholesale

Incheon Pharm (인천약품)

Regional wholesaler

—

Same

Korean pharmaceutical wholesale

Boksan Nice (복산나이스)

Regional wholesaler

—

Same

Korean pharmaceutical wholesale

TJ Pharm (티제이팜)

Wholesaler

—

Same

KOSDAQ crypto-pivot cohort

Hyper Corporation (KOSDAQ 065650)

Peer in "virtual-asset pivot" theme

—

Asia Economy, 11 Aug 2025

KOSDAQ crypto-pivot cohort

Parataxis Korea (KOSDAQ 288330)

Same; largest shareholder became a foreign crypto firm

—

Same

KOSDAQ crypto-pivot cohort

Someage (KOSDAQ 208640)

Same; charter amended for crypto

—

Same

Group comparator

Aprogen Biologics (KOSPI 003060)

Sister listed affiliate

TTM revenue ~KRW 68.6 bn; TTM operating loss ~KRW 57.0 bn

ValueLine (26.1Q)

Group comparator

Aprogen Inc. (KOSPI 007460)

Parent

TTM revenue ~KRW 127.3 bn; TTM operating loss ~KRW 97.5 bn

ValueLine (26.2Q)

Peer Comparison FY2025

MetricAPTOCROM FY2025Aprogen (TTM 26.2Q)Aprogen Biologics (TTM 26.1Q)

Revenue (KRW Bn)

9.81127.368.6

Operating margin (%)

-23.3-76.6-83.1

Market cap (KRW Bn)

~28.5 (Oct 2026)

~67 (27 Aug 2026)

~29.3 (25 Jun 2026)

R&D intensity

—

Not disclosed here

Not disclosed here

“—” = not publicly disclosed.

Recent Developments

Items not identified in the period: product launches, contract wins, layoffs, litigation and regulatory sanctions.

Company Snapshot

$6.9M

Revenue

18

Employees

1998

Founded

Seongnam, South Korea

Headquarters

SWOT Analysis

Strengths

  • Low leverage: total liabilities of KRW 13.9 bn against equity of KRW 306.6 bn (4.5%) at FY2025 (AGM disclosure, 30 Mar 2026).
  • Large book equity relative to market value: P/B of about 0.09x (computed from KRW ~28.5 bn market cap and KRW 306.6 bn equity), which offers a theoretical margin of safety if assets are recoverable.
  • Hard-asset collateral: Seongnam land and buildings in PP&E and investment property, used to secure KRW 5.5 bn of bank lines (KIND Q1 2026).
  • Demonstrated parent support: affiliates committed KRW 25 bn to the 2024 offering (Asia Economy, 8 Oct 2024), and Nexconics put in KRW 12.0 bn in May 2026 (DigitalToday, 28 Apr 2026).
  • Sales-linked economic rights in AP096, with management expecting full investment recovery around 2030 if development succeeds (Asia Economy, 8 Oct 2024).
  • Audit opinion on FY2025 statements was unqualified for both separate and consolidated accounts (AGM, 30 Mar 2026).

Weaknesses

  • Revenue collapse: KRW 21.9 bn (FY2019) → KRW 16.4 bn (FY2024) → KRW 9.81 bn (FY2025) (Asia Economy; DigitalToday).
  • Operating loss of KRW 2.29 bn in FY2025 after KRW 0.97 bn profit in FY2024 (27 Feb 2026 disclosure).
  • Large non-operating losses: FY2024 pre-tax loss of KRW 26.3 bn and net loss of KRW 28.0 bn (same).
  • Thin governance: 1 independent director out of 4 (25%) (DigitalToday, 31 Mar 2026).
  • Tiny organization of about 17–18 employees (Morningstar; Statbase).
  • Identity instability: three corporate names between early 2024 and late 2025 (DigitalToday, 22 Aug 2025).

Opportunities

  • A successful AP096 launch, guided for as early as 2028, would generate dividend inflows (Dealsite, 20 Sep 2024).
  • Regulatory easing for biosimilars could accelerate AP063 and the group's cash generation (Dealsite, 5 Nov 2025).
  • Full collection of the KRW 16 bn balance on the 27th CB sale would add meaningful liquidity versus a KRW ~28.5 bn market cap (DigitalToday, 31 Mar 2026).
  • Deployment of the KRW 12.0 bn placement into an acquisition could add a new revenue line (DigitalToday, 28 Apr 2026). The target is undisclosed.
  • The blockchain/virtual-asset charter gives optionality if Korean digital-asset regulation opens to listed corporates (Asia Economy, 11 Aug 2025).
  • The post-consolidation share price above KRW 1,000 reduces exposure to regulatory penny-stock pressure (Daum/news, 30 Mar 2026).

Threats

  • Concentration of assets in claims on a loss-making parent: Aprogen's TTM operating loss is about KRW 97.5 bn on KRW 127.3 bn revenue (ValueLine).
  • Counterparty slippage: the 27th CB balance has already been rescheduled from Feb to Apr 2026 (and possibly Jun 2026) (DigitalToday, 31 Mar 2026).
  • Minority-shareholder dilution: the 2024 offering issued new shares equal to about 87% of the existing count (Asia Economy, 8 Oct 2024); a further ~37% dilution followed in May 2026 (computed: 4.09 m ÷ 11.04 m).
  • Low free float and liquidity after affiliates reached ~79% ownership (computed). This risks price dislocation and limits institutional participation.
  • Biosimilar execution risk: AP096 was still in clinical-supply and trial stages in 2024–2025 guidance (Dealsite, 20 Sep 2024).
  • Regulatory and reputational scrutiny of KOSDAQ crypto-pivot names (Asia Economy, 11 Aug 2025) and of intra-group circular transactions previously reported by the media (Asia Economy, 6 Feb 2020).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
May 2025Stock at KRW 341, market cap ~KRW 68.5 bn; 1-year price change −42.7% Simply Wall St (19 May 2025 snapshot)Pre-pivot valuation reference
21 May 2025Aprogen agrees to buy a further 20.06% from Aprogen Biologics MarketScreenerControl consolidates at parent level
26 Jun 2025Aprogen's reported stake 53.42% (reporting basis date) DigitalToday, 22 Aug 2025Baseline before increase
6 Aug 2025EGM convened to add crypto/blockchain objects and rename to APTOCROM Asia Economy, 11 Aug 2025Strategic pivot signal
11 Aug 2025Shares hit the +30% limit to KRW 455 on the crypto announcement Asia Economy, 11 Aug 2025Thematic speculation
18 Aug 2025Aprogen buys 40,269,859 shares off-market at KRW 317 DigitalToday, 22 Aug 2025Stake to 71.66%
22 Aug 2025Shares at KRW 398 (+2.84%) on the day of the stake filing DigitalToday, 22 Aug 2025Price reference
22 Aug 2025Name change to APTOCROM approved / disclosed DigitalToday, 22 Aug 2025Second rebrand in ~18 months
24 Oct 2025Third installment (KRW 2 bn) due from the 27th CB buyer DigitalToday, 31 Mar 2026–
Nov 2025Simply Wall St commentary flags weak earnings quality (title: "soft earnings just the beginning of its problems")Third-party sentiment
5 Nov 2025Parent Aprogen outlines a three-pronged strategy (biosimilars, new drugs, CMO) and cites regulatory easing for AP063 Dealsite, 5 Nov 2025Affects value of APTOCROM's biosimilar claims
31 Dec 2025Contractual deadline for the second KRW 35 bn AP096 tranche Dealsite, 20 Sep 2024–
23 Feb 202620:1 reverse split decided; trading halted; stock KRW 193 DigitalToday / Dealsite, 23 Feb 2026Capital restructuring
23 Feb 2026Sister Aprogen Biologics decides a 15:1 reverse split the same day Dealsite, 23 Feb 2026Group-wide restructuring
27 Feb 2026FY2025 preliminary: revenue −40.2% to KRW 9.81 bn; operating loss KRW 2.29 bn; stock KRW 172 DigitalToday, 27 Feb 2026Operating deterioration
30 Mar 2026AGM approves the capital reduction and elects directors; stock KRW 169 DigitalToday, 30 Mar 2026Governance
31 Mar 2026Outside director Lee Jong-seop re-elected; board 4 / 1 independent DigitalToday, 31 Mar 2026Governance
31 Mar 202627th CB sale: KRW 16 bn balance date moved from 20 Feb to 17 Apr 2026 (extendable to 30 Jun 2026); stock KRW 164 DigitalToday, 31 Mar 2026Receivable-collection risk
28 Apr 2026KRW 12.0 bn placement to Nexconics at KRW 2,932 (10% discount to KRW 3,257 base) DigitalToday, 28 Apr 2026Affiliate funding of an undisclosed acquisition
28 Apr 2026Trading suspension announced from 4 May 2026 for share consolidation; stock +10.56% to KRW 178 DigitalToday, 28 Apr 2026Mechanics
6–7 May 2026Capital-reduction record date (6 May); placement payment date (7 May) DigitalTodayShare count resets to ~15.1 m (computed)
14 May 2026Q1 2026 quarterly report filed KINDLatest periodic filing accessible by title
17 Jun 2026Scheduled listing date of placement shares (1-year lock-up) DigitalToday, 28 Apr 2026Supply overhang deferred to mid-2027
30 Jun 2026Outside date for the 27th CB balance (if the issuer extended maturity) DigitalToday, 31 Mar 2026–
15 Jul 2026Stock KRW 1,696 (post-split) Asia Economy quote modulePrice reference
25 Jul 2026Scheduled maturity of the 6th-series BW (KRW 40 bn original) KIND Q1 2026 excerpt–
Aug 2026Parent Aprogen stock KRW 2,365 (27 Aug), market cap ~KRW 67 bn ValueLineParent capacity to support or repay
6–14 Oct 2026Stock KRW 1,867–1,890; market cap ~KRW 282–285 hundred-million (≈KRW 28.5 bn); 52-week range shown as 147–2,950 (mixes pre- and post-split prices) JudalCurrent valuation

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

1 chart
Revenue by Segment: Consolidated revenue fell from KRW 16,400 Mn in FY2024 to KRW 9,810 Mn in FY2025.
Aprogen Healthcare & Games Inc. — Revenue by Segment
Series (KRW Mn)FY2024FY2025
Consolidated revenue16,4009,810
Parent-only (separate) revenue—7,400
Implied subsidiaries' net contribution to revenue—2,410
Parent-only operating income—-1,160
Implied subsidiaries' operating income—-1,130

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. DigitalToday — "AP헬스케어, '앱토크롬'으로 상호 변경" (22 Aug 2025) (digitaltoday.co.kr)
  2. DigitalToday (AI공시) — Aprogen stake increase to 71.66% (22 Aug 2025) (digitaltoday.co.kr)
  3. DigitalToday — 제3자배정 유상증자 결정 (28 Apr 2026) (digitaltoday.co.kr)
  4. Nate/DigitalToday — FY2025 operating loss disclosure (27 Feb 2026) (m.news.nate.com)
  5. Nate/DigitalToday — AGM results incl. capital reduction (30 Mar 2026) (m.news.nate.com)
  6. Nate/DigitalToday — Outside director re-election (31 Mar 2026) (m.news.nate.com)
  7. Nate/DigitalToday — Aprogen 27th CB transfer date change (31 Mar 2026) (m.news.nate.com)
  8. Nate/DigitalToday — 20:1 consolidation decision (23 Feb 2026) (news.nate.com)
  9. Nate/DigitalToday — Trading halt for capital reduction (23 Feb 2026) (news.nate.com)
  10. Nate/DigitalToday — Placement details (28 Apr 2026) (news.nate.com)
  11. Nate/DigitalToday — Trading suspension for share consolidation (28 Apr 2026) (m.news.nate.com)
  12. KIND — APTOCROM Q1 2026 quarterly report (14 May 2026) (kind.krx.co.kr)
  13. Dealsite — 에이프로젠 자회사 2곳 무상감자 결정 (23 Feb 2026) (dealsite.co.kr)
  14. Dealsite — AP헬스케어 500억 규모 일반공모 유증 결정 (20 Sep 2024) (dealsite.co.kr)
  15. Dealsite — 에이프로젠 "바이오시밀러·신약·CMO로 글로벌 공략" (5 Nov 2025) (dealsite.co.kr)
  16. Asia Economy — AP헬스케어, 가상자산 진출에↑ (11 Aug 2025) (view.asiae.co.kr)
  17. Asia Economy — 시가총액 630억 AP헬스케어, 500억 조달 가능할까 (8 Oct 2024) (view.asiae.co.kr)
  18. Asia Economy — 에이프로젠, 이어지는 계열사간 자금거래 (6 Feb 2020) (core.asiae.co.kr)
  19. Asia Economy — 에이프로젠 그룹, 지배구조 단순화 시동 (27 Apr 2020) (core.asiae.co.kr)
  20. Asia Economy — 옵션 거래로 김재섭 회장 지배력 강화 (14 Feb 2020) (core.asiae.co.kr)
  21. Asia Economy (EN) — Aprogen H&G FY2019 results (28 Jan 2020) (asiae.co.kr)
  22. Asia Economy (EN) — Fortress M publishing termination (19 Feb 2021) (cm.asiae.co.kr)
  23. Asia Economy — AP063 global Phase 3 (27 Jul 2023) (core.asiae.co.kr)
  24. NewDaily — AP헬스케어 biosimilar funding role (23 Sep 2024) (biz.newdaily.co.kr)
  25. Newstomato — AP헬스케어 유증 자금조달 '빨간불' (10 Oct 2024) (newstomato.com)
  26. Newstomato (IB Tomato) — 지베이스 에이프로젠 지분 (newstomato.com)
  27. Daum/news — 동전주 퇴출 앞두고 무상감자 급증 (30 Mar 2026) (v.daum.net)
  28. Money Today — 에이프로젠 매각 추진 (16 Aug 2022) (mt.co.kr)
  29. SBS Biz — 에이프로젠 구조조정 (3 Mar 2023) (biz.sbs.co.kr)
  30. Simply Wall St — A109960 profile / past performance / dividends (simplywall.st)
  31. Morningstar — 109960 company profile (morningstar.com.au)
  32. CB Insights — Aprogen Healthcare & Games profile (cbinsights.com)
  33. Statbase — Aprogen Healthcare & Games (109960.KQ) (statbase.ru)
  34. MarketScreener — Aprogen Biologics event log (marketscreener.com)
  35. ValueLine (KR) — Aprogen 007460 income data (valueline.co.kr)
  36. ValueLine (KR) — Aprogen Biologics 003060 income data (valueline.co.kr)
  37. Judal — APTOCROM market data (Oct 2026) (judal.co.kr)
  38. Dealroom — Aprogen (app.dealroom.co)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.